“…Ever since, the pathophysiology, the clinical and radiological image of the said disease is analysed in many bibliographical references. Albeit developments in radiotherapy techniques, such as the Three-Dimensional Conformal Radiation Therapy (3DCRT) and the IntensityModulated Radiation Therapy (IMRT), which offer greater protection to adjacent healthy tissues and, at the same time, increase the dose absorbed by the tumour target, the frequency of RP has not been eliminated (Bucci et al, 2005;Tsoutsou and Koukourakis, 2006;Guckenberger et al, 2010). Although, some inflammatory mediators such as amifostine (Kouvaris et al, 2007) or Toll-like receptor agonism (Wang et al, 2012) have shown evidence of radioprotection in vitro and in vivo studies, RP clearly remains a radiation dosimetric-related morbidity (Zhang et al, 2012).…”